Kinnate Biopharma
Signal active
Organization
Contact Information
Overview
Kinnate Biopharma develops precision oncology therapeutics to treat patients with genomically-defined cancers. Its mission is to expand the reach of targeted therapeutics by developing products for underserved populations.
The company utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine. Its programs include candidates in preclinical development for cancers that are driven by specific oncogenic alterations in either the BRAF kinase gene or in the FGFR2 and FGFR3 kinase genes.
About
Industries
Biotechnology, Health Care, Medical, Biopharma, Therapeutics, Oncology
Founded
2018
Employees
51-100
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Kinnate Biopharma headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical, Biopharma, Therapeutics, Oncology sector. The company focuses on Biotechnology and has secured $14.0B in funding across 72 round(s). With a team of 51-100 employees, Kinnate Biopharma is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Kinnate Biopharma, raised $22.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
3
Investors
2
Lead Investors
0
Total Funding Amount
$194.5M
Details
3
Kinnate Biopharma has raised a total of $194.5M in funding over 3 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2019 | Early Stage Venture | 74.5M | ||
| 2020 | Late Stage Venture | 98.0M | ||
| 2018 | Early Stage Venture | 22.0M |
Investors
Kinnate Biopharma is funded by 27 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Michael Rome | - | FUNDING ROUND - Michael Rome | 22.0M |
| Brett Zbar | - | FUNDING ROUND - Brett Zbar | 22.0M |
| Kinnate Biopharma | - | FUNDING ROUND - Kinnate Biopharma | 22.0M |
| Foresite Capital | - | FUNDING ROUND - Foresite Capital | 22.0M |
Recent Activity
There is no recent news or activity for this profile.